Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

[7] Among men with both DO and BOO that did not improve on alpha-blocker monotherapy, 73% did show symptomatic improvement after 3 months of tolterodine treatment. Urge urinary incontinence ...

Antimuscarinic drugs are the first-line treatment for overactive bladder. However, traditional formulations are associated with a number of adverse effects, most notably dry mouth. A study ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... is an important milestone for the men with unresolved symptoms of ...

The present study was designed to mimic a normal population with overactive bladder. In fact, both treatment-naïve patients and those with previous experience of overactive bladder therapy were ...

Mostly, older women are more prone to an overactive bladder usually, but a recent representative cohort study indicates the number of men with overactive bladder is significantly on the rise.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...